 Antitubercular Agents
"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 0 | 3 | | 2004 | 3 | 1 | 4 | | 2005 | 2 | 1 | 3 | | 2006 | 2 | 3 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 8 | 4 | 12 | | 2012 | 6 | 5 | 11 | | 2013 | 5 | 0 | 5 | | 2014 | 6 | 4 | 10 | | 2015 | 2 | 1 | 3 | | 2016 | 7 | 5 | 12 | | 2017 | 4 | 0 | 4 | | 2018 | 9 | 4 | 13 | | 2019 | 7 | 2 | 9 | | 2020 | 2 | 3 | 5 | | 2021 | 3 | 6 | 9 | | 2022 | 0 | 2 | 2 | | 2023 | 2 | 6 | 8 | | 2024 | 4 | 2 | 6 | | 2025 | 7 | 0 | 7 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Wabwire D, Masheto G, Jean-Philippe P, Sterling TR, Weinberg A, Gupta A. Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics. Clin Infect Dis. 2026 Feb 09; 82(1):e156-e164.
-
Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26.
-
Sordello S, Brock L, Tagliavini A, Federico D, Boulenc X, Pergher M, Huc Claustre E, Metcalf D, Walter ND, Robertson GT, Clary J, Berg A, Mdluli K, Hermann D, Flood D, Upton AM. A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model. Antimicrob Agents Chemother. 2026 Feb 04; 70(2):e0110925.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Hendrix J, Voskuil MI, Obregón-Henao A, Lyons MA, Robertson GT, Moore CM, Walter ND. Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo. Antimicrob Agents Chemother. 2025 Nov 05; 69(11):e0049225.
-
Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, Mirochnick M, Browning R, Wiesner L, George K, Knowles K, De Koker P, Ngocho JS, Fairlie L, Chakhtoura N, Hesseling AC, Decloedt E, Shapiro DE, van Schalkwyk M. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
-
Singh M, Sarhan MO, Damiba NNL, Singh AK, Villabona-Rueda A, Nino-Meza OJ, Chen X, Masias-Leon Y, Ruiz-Gonzalez CE, Ordonez AA, D'Alessio FR, Aboagye EO, Carroll LS, Jain SK. Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun. 2025 Mar 27; 16(1):3003.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Velásquez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875.
-
Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ektnitphong V, Bauman AA, Massoudi LM, Voskuil MI, Robertson GT, Moore CM, Walter ND. Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0131024.
-
Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, Acuña-Villaorduña C, Barry PM, Bastos ML, Carr W, Chami H, Chen LL, Chorba T, Daley CL, Garcia-Prats AJ, Holland K, Konstantinidis I, Lipman M, Battista Migliori G, Parvez FM, Shapiro AE, Sotgiu G, Starke JR, Starks AM, Thakore S, Wang SH, Wortham JM, Nahid P. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025 Jan; 211(1):15-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|